NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Iodohippurate Sodium I-131 is a radioactive diagnostic agent used for renal imaging and kidney function assessment. It is an injectable radiopharmaceutical that localizes in the kidneys to evaluate glomerular filtration and tubular secretion. This product is in pre-launch stage and sponsored by PharmaLundensis.
Pre-Launch
Early-stage pre-launch product with undefined commercial trajectory; team size and investment level cannot be assessed without approval and market entry data.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch diagnostic radiopharmaceutical presents early-career-stage opportunity with roles focused on regulatory navigation, clinical support, and market preparation. Limited current job openings (0 linked positions) reflect pre-commercial status, but approval could rapidly expand team hiring across regulatory, medical affairs, and field operations.
Regulatory Affairs Specialist
Worked on IODOHIPPURATE SODIUM I 131 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.